⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SCNX News
Scienture Holdings, Inc. Common Stock
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
globenewswire.com
SCNX
Form 8-K
sec.gov
SCNX
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
globenewswire.com
SCNX
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
globenewswire.com
SCNX
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
globenewswire.com
SCNX
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
globenewswire.com
SCNX
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
globenewswire.com
SCNX
SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
accessnewswire.com
SCNX
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
globenewswire.com
SCNX
Form 8-K
sec.gov
SCNX